close Video Dr. Marc Siegel on AstraZeneca withdrawing COVID-19 vaccine: I am concerned about the delay Fox News medical analyst Dr. Marc Siegel discusses AstraZeneca withdrawing its COVID-19 vaccine as concerns over side effects grow on 'Special Report.
' A combination COVID-influenza vaccine is apparently one step closer to hitting the market. Moderna, which is developing the experimental vaccine , announced Monday that in phase 3 clinical trials, mRNA-1083 achieved a better immune response than other vaccines. The combination vaccine includes mRNA-1010 (Moderna’s vaccine candidate for seasonal influenza) and mRNA-1283 (the company’s "next-generation COVID-19 vaccine candidate"), according to a press release from the company.
COVID AND FLU VACCINE RATES ARE DECLINING FOR US HEALTH CARE WORKERS, CDC REPORTS: ‘DISTURBING TREND’ "This data serves as a milestone for the industry’s pursuit of a flu and COVID-19 combination vaccine, which could change the way we manage the respiratory illness season," Francesca Ceddia, chief medical affairs officer at Moderna, said in a statement to Fox News Digital. A combination COVID-influenza vaccine is one step closer to hitting the market with this new announcement from Moderna. (iStock) "With mRNA-1083, we may be able to not only offer the convenience of dual protection in a single shot, but we also may offer enhanced immunity compared to today’s standalone vaccines against the two respiratory diseases with the largest burden on.